(Q46381956)

21 December 2017

title

What mediates the benefits associated with dipeptidyl peptidase-IV inhibition? (English)

1 reference

21 December 2017

author name string

B Ahrén

series ordinal

1

1 reference

21 December 2017

publication date

16 March 2005

1 reference

21 December 2017

published in

Diabetologia

1 reference

21 December 2017

volume

48

1 reference

21 December 2017

issue

4

1 reference

21 December 2017

page(s)

605-607

1 reference

21 December 2017

Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice

cites work

1 reference

12 December 2020

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

1 reference

12 December 2020

Intraperitoneal PACAP administration decreases blood glucose in GK rats, and in normal and high fat diet mice

1 reference

12 December 2020

Insulinotropin PACAP potentiates insulin action. Stimulation of glucose uptake in 3T3-LI adipocytes

1 reference

12 December 2020

Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion.

1 reference

12 December 2020

Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans

1 reference

12 December 2020

Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice

1 reference

12 December 2020

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

12 December 2020

The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1.

1 reference

12 December 2020

The neuropeptide pituitary adenylate cyclase-activating polypeptide and islet function

1 reference

12 December 2020

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

1 reference

12 December 2020

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

1 reference

12 December 2020

Dual effects of pituitary adenylate cyclase-activating polypeptide and isoproterenol on lipid metabolism and signaling in primary rat adipocytes

1 reference

12 December 2020

Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

1 reference

12 December 2020

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

1 reference

12 December 2020

Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors

1 reference

12 December 2020

Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

1 reference

12 December 2020

The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38).

1 reference

12 December 2020

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

1 reference

12 December 2020

Autonomic regulation of islet hormone secretion--implications for health and disease

1 reference

12 December 2020

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

1 reference

12 December 2020

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

1 reference

12 December 2020

GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes

1 reference

12 December 2020

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

1 reference

12 December 2020

10.1007/S00125-005-1706-6

Identifiers

DOI

1 reference

21 December 2017

1 reference

21 December 2017